Samsung Eyes $100M Investment in Medical Imaging Startup Exo
▼ Summary
– Samsung’s investment unit is considering investing up to $100 million in Exo, a California-based medical device startup.
– The funding round is led by Sands Capital, Bold Capital, and Qubit Health Capital, with Qubit’s chairman joining Exo’s board.
– Exo develops handheld medical imaging devices that integrate AI, medical imaging, and smartphone connectivity for ultrasound exams.
– The company has raised over $320 million to date, including a $220 million Series C round in 2021.
– Exo is in discussions to partner with Samsung Medison Co., a medical device manufacturer specializing in ultrasound and X-ray systems.
Samsung is reportedly considering a major $100 million investment in Exo, a California-based medical imaging startup specializing in handheld ultrasound technology. According to sources familiar with the matter, the funding round is being spearheaded by Sands Capital, Bold Capital, and Qubit Health Capital, with Qubit’s chairman, Imar Ishrak, expected to join Exo’s board.
Exo has developed an innovative portable ultrasound device that integrates AI, advanced medical imaging, and silicon technology. The compact tool connects to smartphones, allowing healthcare professionals to conduct scans, document findings, and share reports seamlessly through a single app. Applications range from lung examinations to echocardiograms, making it a versatile solution for point-of-care diagnostics.
Since its founding in 2015, Exo has secured over $320 million in funding from prominent investors, including RA Capital Management, BlackRock, Intel, and Sony. The company’s most recent funding round—a $220 million Series C—was completed in 2021.
Industry insiders suggest Exo is also exploring a potential collaboration with Samsung Medison Co., a subsidiary specializing in ultrasound diagnostics and digital X-ray systems. Such a partnership could accelerate the adoption of Exo’s technology in global healthcare markets.
Neither Exo nor the involved investment firms have publicly confirmed the discussions. Samsung’s potential backing signals growing interest in AI-driven medical devices, particularly those enhancing accessibility and efficiency in diagnostics.
(Source: TechCrunch)
